Brief: Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA
17/11/2025 12:49
Nov 17 (Reuters) - Fortress Biotech Inc FBIO.O: FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDA FORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONES Source text: [ID:n0001104659-25-112945] Further company coverage: FBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi